Request Demo

Last update 08 May 2025

Obesity, Metabolically Benign

Last update 08 May 2025

Basic Info

Synonyms

Benign Obesity, Metabolically, Healthy Obesity, Metabolically, Metabolically Benign Obesity

+ [5]

Introduction

A sub-PHENOTYPE of obese individuals who have a risk for CARDIOVASCULAR DISEASES between that of healthy individuals with normal weight and unhealthy individuals with obesity.

Drugs associated with Obesity, Metabolically Benign

Piromelatine

Target

5-HT1A receptor x 5-HT1D receptor x MTNR1A x MTNR1B

Mechanism

5-HT1A receptor antagonists [+3]

Active Org.

Neurim Pharmaceuticals Ltd. [+1]

Originator Org.

Neurim Pharmaceuticals Ltd.

Active Indication

Alzheimer Disease [+2]

Inactive Indication

Sleep Initiation and Maintenance Disorders

Drug Highest PhasePhase 2/3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

MET-3

Target-

Mechanism

Bacteria replacements [+1]

Active Org.

NuBiyota LLC

Originator Org.

NuBiyota LLC

Active Indication

Hypertriglyceridemia

Inactive Indication

Obesity, Metabolically Benign

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

DR10624

Target

FGF21R x GCGR x GLP-1R

Mechanism

FGF21R agonists [+2]

Active Org.

Zhejiang Doer Biologics Co., Ltd. [+1]

Originator Org.

Zhejiang Doer Biologics Co., Ltd.

Active Indication

Fibrosis, Liver [+7]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Obesity, Metabolically Benign

NCT06743009

/ Not yet recruitingNot ApplicableIIT

The Metabolic Effects of the Exercise-metabolite N-lactoyl-phenylalanine (Lac-Phe)

The goal of this double-blinded, randomized cross-over clinical trial is to assess the isolated (i.e. outside the context of exercise) effects of Lac-Phe on appetite and glucose concentrations in healthy volunteers with obesity (BMI 28-35).
The main questions it aims to answer are:
* Does Lac-Phe reduce appetite in humans?
* Does Lac-Phe have glucose-lowering properties in humans?
During the study, participants will:
* receive an intravenous infusion of Lac-Phe on one study day and a NaCl infusion on another study day.
* drink a standard mixed meal
* eat an ad libitum meal test
* answer appetite questionnaires
* indirect calorimetry
* blood samples for hormone and substate analyses

Start Date01 Mar 2025

Sponsor / Collaborator

University of Aarhus

NCT06355544

/ Not yet recruitingNot Applicable

Integrative and Personalized Lifestyle Approach to Reduce Low-Grade Inflammation in People at Risk of Cardiometabolic Diseases

The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
The main questions it aims to answer are:
Whether it is possible to predict low-grade inflammation
What are the medical, biological, and lifestyle variables related to low-grade inflammation?
Participants will be asked to:
Attend a general medical visit to collect vital signs, anthropometric measurements, and collect blood samples.
Complete questionnaires and collect a stool sample at home.

Start Date01 Apr 2024

Sponsor / Collaborator

Institut Pasteur de Lille

[+3]

NCT06297928

/ RecruitingNot ApplicableIIT

Metabolomics and Bariatric Surgery in Patients With Metabolically Unhealthy Obesity: Advancing Precision Medicine for the Treatment of Obesity

The goal of this observational study is to investigate metabolic changes in individuals undergoing bariatric surgery, specifically focusing on those with obesity and varying metabolic health statuses. The main questions it aims to answer are:
Can metabolic markers predict the transition from metabolically unhealthy obesity to metabolically healthy obesity after bariatric surgery?
How do metabolic profiles change in individuals with metabolically healthy obesity after bariatric surgery?
What are the metabolic differences between individuals with metabolically healthy and unhealthy obesity before and after bariatric surgery?
Participants will undergo routine evaluations and blood tests before and after bariatric surgery. These tests will include assessments of metabolic health markers and sampling of blood plasma for metabolomic analysis. The study will study changes in metabolic profiles between individuals who transition to metabolically healthy obesity and those who remain metabolically unhealthy after surgery.

Start Date01 Jan 2024

Sponsor / Collaborator

Consorci Mar Parc de Salut de Barcelona

100 Clinical Results associated with Obesity, Metabolically Benign

100 Translational Medicine associated with Obesity, Metabolically Benign

0 Patents (Medical) associated with Obesity, Metabolically Benign

353

Literatures (Medical) associated with Obesity, Metabolically Benign

01 May 2025·Diabetes, Obesity and Metabolism

GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity

Article

Author: Bisson, Arnaud ; Fauchier, Grégoire ; Ducluzeau, Pierre Henri ; Bucci, Tommaso ; Alam, Uazman ; Lochon, Lisa ; Lip, Gregory Y. H. ; Fauchier, Laurent

AbstractAimsThe associations of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and outcomes among patients with obesity according to the presence of cardiovascular risk factors (metabolically healthy obesity (MHO) or metabolically unhealthy obesity (MUHO)) remain unclear. We examined the associations of GLP‐1RAs with mortality and adverse cardiovascular events in patients with MHO and MUHO.MethodsThe TriNetX network was utilized to select a cohort of patients with MHO or MUHO, and use or non‐use of GLP‐1RAs with propensity score matching (1:1). Cardiovascular events were identified during follow‐up.ResultsA total of 2 983 151 patients with obesity (512 434 with MHO and 2 470 717 with MUHO) were included in the study. Among these, 416 713 (13.9%) were GLP‐1RA users. After propensity score matching, GLP‐1RA use in MUHO was associated with a significantly lower risk of mortality (HR 0.580 [95% CI, 0.566–0.595]), ischemic stroke (HR 0.921 [0.890–0.953]), AF (HR 0.913 [0.888–0.938]) and hospitalization for HF (HR 0.925 [0.900–0.949]) during follow‐up compared with non‐use of GLP‐1RA. Patients with MHO had a markedly lower risk of clinical events than those with MUHO. A trend towards a lower risk of cardiovascular events associated with GLP‐1RA was seen among patients with MHO. There was no statistical interaction in the risk of cardiovascular outcomes with GLP‐1RA use for MHO and MUHO patients.ConclusionsThe use of GLP‐1RAs was associated with lower rates of cardiovascular events than no use in patients with MUHO. Similar but non‐statistically significant trends were seen in patients with MHO.

01 Mar 2025·International Immunopharmacology

Hesperetin mitigates adipose tissue inflammation to improve obesity-associated metabolic health

Article

Author: Chen, Qiu ; Tong, Haibin ; Chen, Wenjun ; Zhang, Beining ; Li, Fang ; Zhu, Qihan ; Zhang, Lin ; Xue, Liwei

Metabolically unhealthy obesity (MUO) poses significant health risks, including increased susceptibility to type 2 diabetes and cardiovascular diseases. Hesperetin is a key bioactive compound found in citrus fruits. Previous studies have shown that hesperetin can correct metabolic abnormalities and mitigate the progression of various metabolic disorders, but the underlying mechanisms remain unclear. Here, we explored the impact of hesperetin on MUO using ob/ob mice and investigated its potential pharmacological mechanisms. The present data indicated that administration of hesperetin for 12 weeks led to notable improvements in metabolic parameters, including reduced fasting blood glucose, fasting insulin levels, and the HOMA-IR index in ob/ob mice. Glucose and insulin tolerance tests demonstrated that hesperetin effectively enhanced insulin sensitivity, with high-dose effects comparable to metformin. Hesperetin treatment decreased inguinal white adipose tissue (iWAT) weight and improved insulin signaling by increasing AKT phosphorylation. Additionally, it reduced the expression of pro-inflammatory cytokines (Il-6 and Il-1β), chemokine Ccl2 and its receptor Ccr2, and macrophage activation markers Nos2 and Ptgs2 within iWAT of ob/ob mice, likely by inhibiting NF-κB activation and macrophage-mediated inflammation. In vitro studies further confirmed hesperetin's anti-inflammatory effects in LPS-stimulated macrophages, where it suppressed cytokine production and NF-κB signaling. Hesperetin also impaired CCL2-induced macrophage chemotaxis, reducing migration velocity and distance. Mechanistically, hesperetin directly interacts with and inhibits IKKβ kinase activity by binding to key residues (LEU21, VAL465, CYS99, and GLU97) and stabilizing the complex, as demonstrated by molecular docking and molecular dynamics simulations. These findings underscore hesperetin's therapeutic potential in mitigating metabolically unhealthy obesity, obesity-induced insulin resistance, and inflammation through direct modulation of the IKKβ and NF-κB pathways.

01 Mar 2025·Obesity Pillars

Prevalence and association of MASLD in metabolically healthy young Asian Americans with obesity: A nationwide inpatient perspective (2019)

Article

Author: Sidhu, Avideep ; Chauhan, Sukhjinder ; Sunkara, Praveena ; Alhomaid, Ahmad ; Desai, Rupak ; Katamreddy, Yamini

BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Although the epidemiology of MASLD and its association with metabolically healthy obesity (MHO) is well-studied in the United States, data for Asian Americans with MHO is limited. We sought to evaluate the association of MASLD in young Asian American patients with MHO.MethodsThis was a retrospective, matched cohort, database review of Asian American Individuals. After excluding adult hospitalizations with metabolic risk factors (hypertension, diabetes, or hyperlipidemia), we identified all National Inpatient Sample (2019) admissions with obesity (MHO) and MASLD using relevant ICD-10-CM codes. We matched (1:1) propensity scores for age, sex, household income, hospital location, and teaching status to obtain cohorts with and without obesity (MHO+) vs. (MHO-). Categorical and continuous data were compared using the Chi-square and Mann-Whitney U tests. The primary endpoint was the prevalence and adjusted multivariable odds/predictors of MASLD in (MHO+) vs. (MHO-) cohort.ResultsIn the adjusted multivariate regression for demographics, and comorbidities, the (MHO+) cohort was associated with higher odds of admissions with MASLD (OR 4.07, 95%CI 2.02-8.19, p < 0.001). In addition, among the (MHO+) cohort, higher rates of MASLD-related hospitalizations were observed in males (OR 8.40, p < 0.001), females (OR 2.69, p = 0.025), high-income quartiles (OR 10.51, p < 0.001), no prior bariatric surgery (OR 4.07, p < 0.001), non-tobacco users(OR 4.16, p < 0.001), and non-hypothyroid patients (OR 4.00, p < 0.001) compared to the (MHO-) cohort. There was no statistically significant difference in the groups with low-income quartiles, tobacco use disorder, and hypothyroidism.ConclusionThis nationwide analysis demonstrates that (MHO+) is associated with a higher prevalence of MASLD. In the (MHO+) cohort, there was an association of MASLD with sex, high-income quartile, no prior bariatric surgery, non-tobacco use, and non-hypothyroidism. Further prospective multicenter studies are needed to evaluate the association of MASLD in (MHO+) patients with comorbid conditions.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Obesity, Metabolically Benign

Basic Info

Related

Analysis